GlassScriptPhysician profile
David M Washington
NPI 1851684955
$4,910.84
in general payments reported to CMS, 2019-2025
33 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $536 · 2021: $520 · 2022: $344 · 2023: $471 · 2024: $672 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,620 · Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,620.00 |
| Food and Beverage | $1,143.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $1,620.00 | 2025 | |
| Novo Nordisk INC | $563.64 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $402.45 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $270.68 | 2019-2022 | |
| Lilly USA, LLC | $249.29 | 2020-2024 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $190.55 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Edwards Lifesciences Corporation | $188.02 | 2023 | The Edwards Sapien 3 Valve With Alterra Adaptive Prestent System |
| Pfizer INC. | $186.88 | 2019-2024 | |
| Amgen INC. | $141.48 | 2019-2022 | |
| Inspire Medical Systems, INC. | $132.86 | 2023-2024 | Inspire |
| Abbott Laboratories | $124.43 | 2022-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $116.90 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $106.36 | 2019-2024 | Contrave |
| Otsuka America Pharmaceutical, INC. | $103.97 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $94.81 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.98 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $37.58 | 2019-2020 | |
| Abbvie INC. | $35.29 | 2024 | |
| Exact Sciences Corporation | $34.66 | 2023-2024 | Cologuard Collection Kit |
| Nalpropion Pharmaceuticals LLC | $30.40 | 2019 | |
| Dynavax Technologies Corporation | $25.65 | 2023 | Heplisav-B |
| Alnylam Pharmaceuticals INC. | $21.33 | 2024 | Givlaari |
| Antares Pharma, INC. | $20.73 | 2024 | Xyosted |
| Janssen Pharmaceuticals, INC | $19.87 | 2021 | |
| Astellas Pharma US INC | $19.66 | 2020 | |
| Horizon Therapeutics Plc | $17.74 | 2023 | Krystexxa |
| Shire North American Group INC | $17.02 | 2019 | |
| Sanofi Pasteur INC. | $16.30 | 2019 | |
| Cranial Technologies, INC | $14.69 | 2019 | |
| Alk-Abello, INC | $14.48 | 2024 | Odactra, Grastek |
| Biohaven Pharmaceuticals, INC. | $14.38 | 2021 | |
| Insulet Corporation | $12.59 | 2019 | |
| Phadia US INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.